Biohaven Pharmaceutical Holding Company

Biohaven Pharmaceutical Holding Company

World Rank (Aug-2026)
6000
Market Cap (Aug-2026)
2.211 Billion USD
Market Cap (Mar-08-2026)
1.492 Billion USD
World Rank (Jan-05-2024)
3,972
Market Cap (Jan-05-2024)
3.399 Billion USD
World Rank (Jul-30-2023)
7,470
Market Cap (Jul-30-2023)
1.300 Billion USD
World Rank (Jan-07-2022)
2,147
Market Cap (Jan-07-2022)
8.441 Billion USD
World Rank (Jan-01-2021)
2,858
Market Cap (Jan-01-2021)
5.137 Billion USD
Headquarters Country
USA
Top Healthcare Companies in USA
Top Pharmaceutical Companies in USA
Nasdaq / NYSE Code
BHVN
Employee Count
797
Employee Count as of Date
As on 2021
Headquarters City/State
Connecticut
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
463 Million USD
Annual Operating Income in USD
-704 Million USD
Annual Net Income in USD
-847 Million USD
Annual Results for Period Ending
For year ending December-2021
Total Assets in USD
1,077 Million USD
Total Liabilities in USD
1,760 Million USD
Total Equity in USD
-743 Million USD
Balance Sheet for Period Ending
As of December-2021
Business Sector
Healthcare
Pharmaceutical
HealthCare Products
Biotechnology
Company Website
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Yahoo
Yahoo @ NYSE
Company Profile

Biohaven Pharmaceutical Holding Company is a Clinical Stage Biopharmaceutical company. It portfolio is comprised of innovative, late stage product candidates targeting neurological and neuropsychiatric diseases including rare disorders. The company is rapidly progressing multiple compounds in clinical trials across three platforms they are calcitonin gene related peptide receptor antagonism, glutamate modulation and myeloperoxidase inhibition. The headquarters is in USA.

Annual Results Summary

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueGross ProfitOperating IncomeNet Income
Dec-2021462370-704 (Loss)-846 (Loss)
Dec-20206345-645 (Loss)-766 (Loss)
Dec-20190--479 (Loss)-528 (Loss)
Dec-20180--224 (Loss)-240 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2021 was 1,077 Million USD.

Total Liabilities as on Dec-2021 was 1,760 Million USD.

Total Equity as on Dec-2021 was -683 Million USD.

Founded Year
2013
IPO Year
2022
Stock Exchange
NYSE
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share